tiprankstipranks
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
AVBP
ArriVent BioPharma, Inc.
RESEARCH TOOLSreports
Want to see AVBP full AI Analyst Report?

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

81 Followers
See the Price Targets and Ratings of:

AVBP Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
ArriVent
BioPharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$44.33
▲(49.57% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $44.33 with a high forecast of $50.00 and a low forecast of $42.00. The average price target represents a 49.57% change from the last price of $29.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","34":"$34","51":"$51","25.5":"$25.5","42.5":"$42.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25.5,34,42.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.99,31.529230769230768,33.068461538461534,34.607692307692304,36.14692307692307,37.68615384615384,39.22538461538461,40.76461538461538,42.30384615384615,43.84307692307692,45.38230769230769,46.92153846153846,48.46076923076923,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.99,31.09333333333333,32.196666666666665,33.3,34.40333333333333,35.50666666666666,36.61,37.71333333333333,38.81666666666666,39.919999999999995,41.023333333333326,42.126666666666665,43.23,{"y":44.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.99,30.91384615384615,31.837692307692308,32.761538461538464,33.68538461538461,34.60923076923077,35.53307692307692,36.456923076923076,37.38076923076923,38.30461538461539,39.22846153846154,40.152307692307694,41.076153846153844,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$44.33Lowest Price Target$42.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
B. Riley Securities Analyst forecast on AVBP
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$45
Buy
51.82%
Upside
Reiterated
05/19/26
Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)
LifeSci Capital Analyst forecast on AVBP
Sam Slutsky
LifeSci Capital
LifeSci Capital
$42
Buy
41.70%
Upside
Reiterated
05/16/26
LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
Oppenheimer Analyst forecast on AVBP
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
68.69%
Upside
Reiterated
05/13/26
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer
Citi Analyst forecast on AVBP
Yigal Nochomovitz
Citi
Citi
$45→$43
Buy
45.07%
Upside
Assigned
05/13/26
ArriVent Biopharma price target lowered to $43 from $45 at CitiArriVent Biopharma price target lowered to $43 from $45 at Citi
JonesTrading Analyst forecast on AVBP
Boris Peaker
JonesTrading
JonesTrading
$40→$45
Buy
51.82%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Hims & Hers Health (NYSE: HIMS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
H.C. Wainwright Analyst forecast on AVBP
Robert Burns
H.C. Wainwright
H.C. Wainwright
$44
Buy
48.45%
Upside
Reiterated
05/12/26
H.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Guggenheim Analyst forecast on AVBP
Michael Schmidt
Guggenheim
Guggenheim
$45
Buy
51.82%
Upside
Reiterated
04/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Oncolytics Biotech (NASDAQ: ONCY)
BTIG Analyst forecast on AVBP
Jeet Mukherjee
BTIG
BTIG
$42
Buy
41.70%
Upside
Initiated
03/12/26
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
Truist Financial Analyst forecast on AVBP
Asthika Goonewardene
Truist Financial
Truist Financial
$43
Buy
45.07%
Upside
Reiterated
03/06/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Evommune, Inc. (NYSE: EVMN)
Cantor Fitzgerald Analyst forecast on AVBP
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/22/25
ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Clear Street Analyst forecast on AVBP
Kaveri Pohlman
Clear Street
Clear Street
$32→$47
Buy
58.57%
Upside
Reiterated
11/11/25
ArriVent Biopharma price target raised to $47 from $32 at Clear StreetArriVent Biopharma price target raised to $47 from $32 at Clear Street
Wolfe Research Analyst forecast on AVBP
Kalpit Patel
Wolfe Research
Wolfe Research
$37
Buy
24.83%
Upside
Reiterated
07/21/25
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial
Goldman Sachs Analyst forecast on AVBP
Corinne Johnson
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
B. Riley Securities Analyst forecast on AVBP
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$45
Buy
51.82%
Upside
Reiterated
05/19/26
Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)
LifeSci Capital Analyst forecast on AVBP
Sam Slutsky
LifeSci Capital
LifeSci Capital
$42
Buy
41.70%
Upside
Reiterated
05/16/26
LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
Oppenheimer Analyst forecast on AVBP
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
68.69%
Upside
Reiterated
05/13/26
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer
Citi Analyst forecast on AVBP
Yigal Nochomovitz
Citi
Citi
$45→$43
Buy
45.07%
Upside
Assigned
05/13/26
ArriVent Biopharma price target lowered to $43 from $45 at CitiArriVent Biopharma price target lowered to $43 from $45 at Citi
JonesTrading Analyst forecast on AVBP
Boris Peaker
JonesTrading
JonesTrading
$40→$45
Buy
51.82%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Hims & Hers Health (NYSE: HIMS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
H.C. Wainwright Analyst forecast on AVBP
Robert Burns
H.C. Wainwright
H.C. Wainwright
$44
Buy
48.45%
Upside
Reiterated
05/12/26
H.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Guggenheim Analyst forecast on AVBP
Michael Schmidt
Guggenheim
Guggenheim
$45
Buy
51.82%
Upside
Reiterated
04/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Oncolytics Biotech (NASDAQ: ONCY)
BTIG Analyst forecast on AVBP
Jeet Mukherjee
BTIG
BTIG
$42
Buy
41.70%
Upside
Initiated
03/12/26
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
Truist Financial Analyst forecast on AVBP
Asthika Goonewardene
Truist Financial
Truist Financial
$43
Buy
45.07%
Upside
Reiterated
03/06/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Evommune, Inc. (NYSE: EVMN)
Cantor Fitzgerald Analyst forecast on AVBP
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/22/25
ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Clear Street Analyst forecast on AVBP
Kaveri Pohlman
Clear Street
Clear Street
$32→$47
Buy
58.57%
Upside
Reiterated
11/11/25
ArriVent Biopharma price target raised to $47 from $32 at Clear StreetArriVent Biopharma price target raised to $47 from $32 at Clear Street
Wolfe Research Analyst forecast on AVBP
Kalpit Patel
Wolfe Research
Wolfe Research
$37
Buy
24.83%
Upside
Reiterated
07/21/25
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial
Goldman Sachs Analyst forecast on AVBP
Corinne Johnson
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

3 Months
Michael SchmidtGuggenheim
Success Rate
8/9 ratings generated profit
89%
Average Return
+8.21%
Copying Michael Schmidt's trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +8.21% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
9/9 ratings generated profit
100%
Average Return
+30.79%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.79% per trade.
2 Years
Michael SchmidtGuggenheim
Success Rate
9/9 ratings generated profit
100%
Average Return
+32.09%
Copying Michael Schmidt's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
17
10
14
11
16
Buy
3
3
3
5
8
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
13
17
16
24
In the current month, AVBP has received 24 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 44.33.
Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$0.97 with a range of -$1.03 to -$0.76. The previous quarter’s EPS was -$0.96. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
Next quarter’s earnings estimate for AVBP is -$0.97 with a range of -$1.03 to -$0.76. The previous quarter’s EPS was -$0.96. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?
Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 44.33.
    What is AVBP’s upside potential, based on the analysts’ average price target?
    ArriVent BioPharma, Inc. has 49.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVBP a Buy, Sell or Hold?
          ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is ArriVent BioPharma, Inc.’s price target?
            The average price target for ArriVent BioPharma, Inc. is 44.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $42.00. The average price target represents 49.57% Increase from the current price of $29.64.
              What do analysts say about ArriVent BioPharma, Inc.?
              ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of AVBP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.